

REMARKS

In the Office Action, the Examiner has imposed a restriction requirement under 35 U.S.C. §§ 121 and 372 and, pursuant to 37 C.F.R. § 1.499, has required election of one of the following inventions:

- I: Claims 1-4, 10, and 11, which are drawn to a nucleic acid encoding a CaKRE5 protein (*e.g.* SEQ ID NO: 1), nucleic acids that hybridize thereto and methods of detecting a nucleic acid in a sample.
- II: Claims 1-3, 5, 10, and 11, which are drawn to a nucleic acid encoding a CaLAR1 protein (*e.g.* SEQ ID NO: 3), nucleic acids that hybridize thereto and methods of detecting a nucleic acid in a sample.
- III: Claims 1-3, 6, 10, and 11, which are drawn to a nucleic acid encoding a CaCDC24 protein (*e.g.* SEQ ID NO: 5), nucleic acids that hybridize thereto and methods of detecting a nucleic acid in a sample.
- IV: Claims 7, 12, 15, 19, 20, 24, and 25, drawn to a CaKRE5 protein (*e.g.* SEQ ID NO: 2) and methods of selecting a compound that modulates the activity of a CaKRE5 protein or which has antifungal activity.
- V: Claims 8, 13, 16, 19, 20, 24, and 25, drawn to a CaALR1 protein (*e.g.* SEQ ID NO: 4) and methods of selecting a compound that modulates the activity of a CaALR1 protein or which has antifungal activity.
- VI: Claims 9, 14, 17, 19, 20, 24, and 25, drawn to a CaCDC24 protein (*e.g.* SEQ ID NO: 6) and methods of selecting a compound that modulates the activity of a CaCDC24 protein or which has antifungal activity.
- VII: Claim 18, which is drawn to an antibody having specific binding affinity for a CaKRE5 protein (*e.g.* SEQ ID NO: 2).
- VIII: Claim 26, which is drawn to an antibody having specific binding affinity for a CaALR1 protein (*e.g.* SEQ ID NO: 4).
- IX: Claim 27, which is drawn to an antibody having specific binding affinity for a CaCDC24 protein (*e.g.* SEQ ID NO: 6).

In response, Applicants hereby elect the invention of Group II (Claims 1-3, 5,

10, and 11, drawn to a nucleic acid encoding a CaLAR1 protein (e.g. SEQ ID NO: 3), nucleic acids that hybridize thereto and methods of detecting a nucleic acid in a sample), for examination on the merits.

CONCLUSION

Applicants respectfully request that the present remarks be made of record in the instant application. An early allowance of the application is earnestly requested. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,

Date: March 28, 2005

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

By: Michael J. Ryan 41,283
Michael J. Ryan (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939